Sugi Predict

Sugi Predict / Compounds / SCHEMBL4476543

SCHEMBL4476543

SCHEMBL4476543

Nc1ncnc2sc(Br)c(-c3ccc(NC(=O)Nc4ccc(F)c(C(F)(F)F)c4)cc3)c12

nearest known ligand 0.61

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ KDR P35968 19/20 0.61
▸ TEK Q02763 14/20 0.61
▸ KIT P10721 13/20 0.61
▸ LCK P06239 3/20 0.61
▸ CSF1R P07333 3/20 0.61
▸ FGFR1 P11362 3/20 0.61
▸ FLT1 P17948 3/20 0.61
▸ FLT4 P35916 3/20 0.61
▸ FLT3 P36888 3/20 0.61
▸ FGFR3 P22607 2/20 0.61
▸ PDGFRB P09619 1/20 0.61
▸ PDGFRA P16234 1/20 0.61
▸ FGFR2 P21802 1/20 0.61
▸ FGFR4 P22455 1/20 0.61
▸ RIPK1 Q13546 1/20 0.61
▸ PLK4 O00444 2/20 0.56
▸ AURKA O14965 2/20 0.56
▸ DYRK3 O43781 2/20 0.56
▸ MAP4K4 O95819 2/20 0.56
▸ FYN P06241 2/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4467021 0.89 KDR (0.76) KDRTEKKITLCKCSF1R
SCHEMBL4473569 0.86 KDR (0.75) KDRTEKKITLCKCSF1R
SCHEMBL6092489 0.86 KDR (0.81) KDRTEKKITLCKCSF1R
SCHEMBL4466605 0.85 KDR (0.77) KDRTEKKITLCKCSF1R
SCHEMBL4477053 0.85 KDR (0.80) KDRTEKKITLCKCSF1R
SCHEMBL4473352 0.84 KDR (0.79) KDRTEKKITLCKCSF1R
SCHEMBL4468059 0.82 KDR (0.79) KDRTEKKITLCKCSF1R
SCHEMBL4473510 0.82 KDR (0.68) KDRTEKKITLCKCSF1R
SCHEMBL4484163 0.82 KDR (0.72) KDRTEKKITLCKCSF1R
SCHEMBL4466025 0.82 KDR (0.82) KDRTEKKITLCKCSF1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-1487841-B1 THIOPYRIMIDINE AND ISOTHIAZOLOPYRIMIDINE KINASE INHIBITORS ABBVIE INC (US) 2014-01-15 — — EP disclosed
US-7560552-B2 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES (US) 2009-07-14 — — US disclosed
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors MICHAELIDES MICHAEL R 2006-12-07 — — US disclosed
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBVIE INC. 2004-01-22 — — US disclosed
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABBOTT LABORATORIES 2003-12-04 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040014756-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885
US-20060276490-A1 Thiopyrimidine and isothiazolopyrimidine Kinase Inhibitors ABL1, LCK, ERBB2 KDR 391/4885TEK 324/4885KIT 361/4885
US-20030225273-A1 Thiopyrimidine and isothiazolopyrimidine kinase inhibitors ABL1, ERBB2, LCK KDR 425/4885TEK 328/4885KIT 394/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.